• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AVROBIO Inc. (Amendment)

    2/13/24 2:15:41 PM ET
    $AVRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVRO alert in real time by email
    SC 13G/A 1 avrb-sc13ga_123123.htm AMENDMENT TO FORM SC 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2 _)*

     

    Avrobio, Inc. 

     

    (Name of Issuer)

     

    Common Stock

     

     (Title of Class of Securities)

     

    05455M100

     

     (CUSIP Number)

     

    December 31, 2023 

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☒  Rule 13d-1(b)
    ☐  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

      

     

    CUSIP No. 05455M100 13G/A Page 2 of 6

     

    1. NAMES OF REPORTING PERSONS

    GMT Capital Corp.                           
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Georgia, United States of America
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    0
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%1
    12. TYPE OF REPORTING PERSON (see instructions)

    IA
           

    1 Calculated based on 44,573,911 shares of common stock of the Issuer (the “Common Stock”) outstanding as of November 2, 2023, as reported on the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2023.

     

     

     

      

     

    CUSIP No. 05455M100 13G/A Page 3 of 6

     

    1. NAMES OF REPORTING PERSONS

    Thomas E. Claugus                           
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    0
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%1
    12. TYPE OF REPORTING PERSON (see instructions)

    HC
           
    1 Calculated based on 44,573,911 shares of common stock of the Issuer (the “Common Stock”) outstanding as of November 2, 2023, as reported on the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2023.

     

     

     

     

     

    CUSIP No. 05455M100 13G/A Page 4 of 6

     

    Item 1.

     

    (a)Name of Issuer

     

    The name of the issuer is Avrobio, Inc. (herein referred to as “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices

     

    The principal executive offices of the Issuer are located at 100 Technology Square, Sixth Floor

     

    Cambridge, Massachusetts 02139

     

    Item 2.

     

    (a)Name of Persons Filing

     

    This Statement is being filed jointly on behalf of each of the following persons (collectively, the “Reporting Persons”)

     

    i)GMT Capital Corp. (“GMT Capital”) with respect to shares of Common Stock directly owned by each of Bay Resource Partners, L.P. (“Bay”), Bay II Resource Partners, L.P. (“Bay II”), Bay Resource Partners Offshore Master Fund, L.P. (“Bay Offshore”) and certain sub-advisory and separate account clients advised by GMT Capital (together with Bay, Bay II and Bay Offshore, collectively, the “Managed Funds and Accounts”).

    ii)Thomas E. Claugus, the control person of GMT Capital, with respect to the shares of Common Stock directly owned by the Managed Funds and Accounts.

     

    (b)Address of the Principal Office or, if none, residence

     

    The address of the business office of each of the Reporting Persons is 2300 Windy Ridge Parkway, Ste. 550 South

     

    Atlanta, GA 30339.

     

    (c)Citizenship

     

    GMT Capital is a Georgia corporation. 

    Mr. Claugus is a citizen of the United States.

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    05455M100 

     

     

     

     

     
    CUSIP No: 05455M100 13G/A Page 5 of 6

     

    Item 3. Filing pursuant to §240.13d-1(c)

     

    If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a :

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.D. 78o):

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

    (e)☒ An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);

    (f)☐ An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);

    (g)☒ A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)☐ A non-U.S. institution in accordance with Sec. 240.13d-1(b)(1)(ii)(J);

    (k)☐ Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J). 

     

    Item 4. Ownership

     

    See Rows 5 through 11 of each Reporting Person’s cover page.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

     

    Item 6. Ownership of More than Five Percent on Behalf of another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Thomas E. Claugus is the President of GMT Capital and in that capacity directs the operations GMT Capital, including the voting and disposition of shares held by the Managed Funds and Accounts.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

     

     
    CUSIP No. 05455M100

     13G/A

    Page 6 of 6

     

    Item 10. Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

      February 12, 2024
      Date

     

    GMT Capital Corp.

     

    By: /s/ Omar Z. Idilby 

     
    Name: Omar Z. Idilby
    Title:  General Counsel and CCO
     

     

    /s/ Thomas E. Claugus. 

     

     
    Thomas E. Claugus, Omar Z. Idilby, attorney in fact*
     

     

    *Omar Z. Idilby is signing on behalf of Thomas E. Claugus as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by GMT Capital Corp. on Schedule 13G for Hudbay Minerals Inc. on 2/12/24.

     

     

    Get the next $AVRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVRO

    DatePrice TargetRatingAnalyst
    12/18/2023Buy → Neutral
    Mizuho
    1/6/2022$28.00 → $6.00Buy
    Mizuho
    1/5/2022$22.00 → $6.00Overweight
    Barclays
    1/5/2022$7.00 → $3.00Equal-Weight
    Morgan Stanley
    1/5/2022Buy → Neutral
    BTIG
    1/5/2022$28.00 → $8.00Buy
    Needham
    11/19/2021$24.00 → $7.00Overweight → Equal-Weight
    Morgan Stanley
    10/12/2021$27.00 → $25.00Overweight
    Morgan Stanley
    More analyst ratings

    $AVRO
    SEC Filings

    See more
    • AVROBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/25/24 9:52:20 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

      6/20/24 4:25:03 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 8-K/A filed by AVROBIO Inc.

      8-K/A - AVROBIO, Inc. (0001681087) (Filer)

      6/18/24 11:51:59 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Leonard Braden Michael bought $971,493 worth of shares (766,635 units at $1.27) (SEC Form 4)

      4 - AVROBIO, Inc. (0001681087) (Issuer)

      5/15/24 11:21:34 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVROBIO downgraded by Mizuho

      Mizuho downgraded AVROBIO from Buy to Neutral

      12/18/23 8:06:56 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho reiterated coverage on Avrobio with a new price target

      Mizuho reiterated coverage of Avrobio with a rating of Buy and set a new price target of $6.00 from $28.00 previously

      1/6/22 6:59:42 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on Avrobio with a new price target

      Barclays reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $6.00 from $22.00 previously

      1/5/22 9:51:19 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

      Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and topline Phase 1B data expected in 2025 Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fu

      3/26/24 7:06:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tectonic Therapeutic Announces Participation at Investor Conferences in March

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March: TD Cowen 44th Annual Health Care Conference being held in Boston on March 4 – 6 Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13 The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink rep

      2/27/24 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

      Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str

      6/3/24 4:15:00 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO and Tectonic Therapeutic Announce Merger

      Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to advance lead asset TX45, a potential best-in-class Fc-relaxin fusion protein, through multiple clinical data catalysts Tectonic's first two programs address indications with high unmet need and no approved therapies Companies to host joint webcast to

      1/30/24 8:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

      On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated Announced appointment of current CFO Erik Ostrowski as interim CEO AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a l

      5/11/23 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Former 10% owner of AVROBIO Leonard Braden Michael acquired 433,688 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/25/24 1:42:11 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donenberg Phillip B.

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:37:33 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vitorovic Stefan was granted 1,028,674 shares (SEC Form 4)

      4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

      6/24/24 4:35:35 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Financials

    Live finance-specific insights

    See more
    • AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

      Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned for 2022; third patient dosed in Phase 1/2 clinical trial Regulatory interactions planned in 2022 to inform clinical development and registration strategies for programs in Gaucher disease, cystinosis, Hunter syndrome and Pompe disease Strong balance sheet with cash runway into Q1 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li

      3/17/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

      Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no adverse events related to drug product to date Clinical proof-of-concept in adult patients lays groundwork for AVROBIO-sponsored trial planned to begin in 2023 Analyst and investor conference call scheduled for today at 8:00 a.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported

      2/9/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

      Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as we

      1/27/22 7:00:00 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/26/24 8:00:02 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by AVROBIO Inc.

      SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)

      6/25/24 4:23:25 PM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by AVROBIO Inc. (Amendment)

      SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)

      5/21/24 10:01:24 AM ET
      $AVRO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care